Skip to content

US · GALT · BIOTECHNOLOGY

Galectin Therapeutics Inc. (GALT) intrinsic value and stock valuation

$2.69as of 2026-11-21 · Mkt cap 227.21M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Galectin Therapeutics Inc. DCF and intrinsic value

InvestorsCraft values GALT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from GALT’s statements →

Galectin Therapeutics Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Norcross, GA 30071 galectintherapeutics.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-30.84M
20112025
Free cash flow
-$-23.88M
20112025
Total equity
-$-126.19M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-20.09M-$-42.43M-$-38.07M-$-38.35M-$-30.18M
Net income-$-30.84M-$-47.05M-$-41.07M-$-38.78M-$-30.53M
EPSd-$-482.63K-$-755.1K-$-682.68K-$-652.97K-$-521.61K
Operating cash flow-$-23.88M-$-41.77M-$-32.97M-$-31.06M-$-24.31M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-23.88M-$-41.77M-$-32.97M-$-31.06M-$-24.31M
Total assets$19.5M$17.5M$28.2M$21.3M$41.8M
Total debt$133.8M$106.3M$71.8M$39.9M$29.1M
Net debt$116M$91.1M$46.2M$21.3M-$-10.59M
Total equity-$-126.19M-$-103.07M-$-60.24M-$-32.19M$2.62M
Cash and short-term investments$17.7M$15.1M$25.7M$18.6M$39.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$14.3M$36.6M$32.1M$31.7M$23.8M
Selling, general and administrative expenses$5.79M$5.86M$5.94M$6.62M$6.36M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$20.1M$42.4M$38.1M$38.4M$30.2M
Cost and expenses$20.1M$42.4M$38.1M$38.4M$30.2M
Interest income$130K$340K$230K$50K$0.00
Interest expense$7.33M$5.54M$2.79M$1.03M$490K
Depreciation and amortization$50K$40K$30K$30K$40K
Ebitda-$-23.45M-$-41.47M-$-38.24M-$-37.71M-$-30M
Operating income-$-20.09M-$-42.43M-$-38.07M-$-38.35M-$-30.18M
Total other income/expenses, net-$-10.75M-$-4.61M-$-2.99M-$-420K-$-350K
Income before tax-$-30.84M-$-47.05M-$-41.07M-$-38.78M-$-30.53M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-30.84M-$-47.05M-$-41.07M-$-38.78M-$-30.53M
Weighted average shares outstanding$63.9M$62.3M$60.2M$59.4M$58.5M
Weighted average diluted shares outstanding$63.9M$62.3M$60.2M$59.4M$58.5M
Balance sheet
20252024202320222021
Cash and short-term investments$17.7M$15.1M$25.7M$18.6M$39.7M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$19.4M$17.3M$27.7M$20.6M$41.8M
Property, plant and equipment, net$0.00$0.00$50K$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$100K$240K$490K$730K$10K
Total assets$19.5M$17.5M$28.2M$21.3M$41.8M
Accounts payable$3.25M$5.66M$6.43M$3.89M$1.8M
Short-term debt$20K$21.1M$50K$40K$10K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$8.03M$35.4M$15.7M$13M$9.03M
Long-term debt$133.7M$85.1M$71.8M$39.8M$29.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$137.7M$85.2M$72.8M$40.5M$30.2M
Capital lease obligations$20K$20K$70K$40K$10K
Total liabilities$145.7M$120.6M$88.4M$53.5M$39.2M
Common stock$70K$60K$60K$60K$60K
Retained earnings-$-432.55M-$-401.57M-$-354.37M-$-309.57M-$-270.69M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity-$-126.19M-$-103.07M-$-60.24M-$-32.19M$2.62M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$133.8M$106.3M$71.8M$39.9M$29.1M
Net debt$116M$91.1M$46.2M$21.3M-$-10.59M
Cash flow statement
20252024202320222021
Net income-$-30.84M-$-47.05M-$-41.07M-$-38.78M-$-30.53M
Depreciation and amortization$50K$40K$30K$30K$40K
Stock-based compensation$1.66M$2.45M$2.26M$2.87M$2.08M
Change in working capital$610K$2.28M$4.68M$4.97M$3.75M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-6.04M-$-2.07M$2.67M$4.24M$3.69M
Net cash provided by operating activities-$-23.88M-$-41.77M-$-32.97M-$-31.06M-$-24.31M
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities$0.00$0.00$0.00$0.00$0.00
Common stock issued$5.47M$1.23M$0.00$0.00$6.81M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-90K$0.00$0.00-$-170K
Net cash used for financing activities$26.5M$31.2M$40M$10M$36.8M
Net change in cash$2.6M-$-10.54M$7.07M-$-21.06M$12.5M
Cash at end of period$17.7M$15.1M$25.7M$18.6M$39.7M
Operating cash flow-$-23.88M-$-41.77M-$-32.97M-$-31.06M-$-24.31M
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-23.88M-$-41.77M-$-32.97M-$-31.06M-$-24.31M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Galectin Therapeutics Inc.

        Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.

        CEO
        Joel Lewis
        Employees
        9
        Beta
        0.35

        Explore

        Frequently asked questions

        What is the intrinsic value of Galectin Therapeutics Inc. (GALT)?

        InvestorsCraft does not currently publish an intrinsic value for GALT. How the IC value is calculated.

        Is GALT undervalued?

        InvestorsCraft does not publish an undervaluation signal for GALT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.